Cigna Finalizes Purchase of Express Scripts

Article

Cigna recently announced the completion of its $54-billion purchase of Express Scripts.

Amid mounting antitrust scrutiny of CVS Health’s acquisition of Aetna, Cigna recently announced the completion of its $54-billion purchase of Express Scripts, according to a press release.

The companies have said that the acquisition will focus on expanding choices including a full suite of medical, behavioral, and specialty pharmacy, and other health care services. According to a Reuters article, Cigna will start offering new products next year to its corporate health insurance customers, including access to Express Scripts’ specialty pharmacy.

According to Cigna, the combination integrates 2 complementary health service companies that are positioned to deliver better care, expand choices, and drive down health care costs.

“Today’s closing represents a major milestone in Cigna’s drive to transform our health care system for our customers, clients, partners, and communities,” David M. Cordani, president and chief executive officer of Cigna, said in a statement. “Together, we are establishing a blueprint for personalized, whole person health care, further enhancing our ability to put the customer at the center of all we do by creating a flexible, open and connected model that improves affordability, choice and predictability. By approaching each individual as a whole person—body and mind as one—we are empowering and supporting customers to take control of their total health and well-being.”

Click to continue reading on Specialty Pharmacy Times.

Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
man taking opioid pills sitting at a dark table - Image credit: rohane | stock.adobe.com
schizophrenic man - mental disorder - Image credit: Andreza | stock.adobe.com
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
A panel of 3 experts on hepatic encephalopathy
A panel of 3 experts on hepatic encephalopathy
© 2024 MJH Life Sciences

All rights reserved.